Jean‐luc Harousseau
#124,522
Most Influential Person Now
Jean‐luc Harousseau's AcademicInfluence.com Rankings
Jean‐luc Harousseauphilosophy Degrees
Philosophy
#5783
World Rank
#8681
Historical Rank
Logic
#2999
World Rank
#4090
Historical Rank
Download Badge
Philosophy
Jean‐luc Harousseau's Degrees
- Doctorate Medicine University of Nantes
Why Is Jean‐luc Harousseau Influential?
(Suggest an Edit or Addition)Jean‐luc Harousseau's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma (1996) (2706)
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
- International uniform response criteria for multiple myeloma (2006) (2014)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (2005) (1965)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
- Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. (2007) (1389)
- Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. (2012) (1017)
- Single versus double autologous stem-cell transplantation for multiple myeloma. (2003) (1015)
- A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. (1996) (932)
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. (2007) (879)
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. (2011) (877)
- Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial (2007) (874)
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011) (862)
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma (2017) (776)
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
- Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. (2006) (662)
- Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. (1997) (551)
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (2010) (523)
- International uniform response criteria for multiple myeloma (2006) (519)
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. (2007) (506)
- Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. (2003) (445)
- Proteasome inhibitors in multiple myeloma: 10 years later. (2012) (438)
- Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. (2002) (417)
- Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). (2010) (413)
- A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases (2003) (395)
- Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. (2010) (365)
- Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. (2008) (355)
- Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. (2006) (355)
- Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. (2006) (354)
- Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. (2002) (338)
- Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. (2001) (319)
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. (2002) (314)
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. (2011) (313)
- Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival (2005) (311)
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline (2009) (300)
- Thalidomide for treatment of multiple myeloma: 10 years later. (2008) (296)
- Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. (2012) (285)
- Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. (2011) (285)
- Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. (2004) (263)
- Prognostic significance of copy-number alterations in multiple myeloma. (2009) (261)
- Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2007) (259)
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. (2018) (254)
- Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. (2001) (251)
- The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. (2006) (246)
- Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. (1994) (238)
- Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. (2004) (236)
- Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia (2005) (234)
- The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement (2007) (222)
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients (1998) (222)
- 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. (1999) (222)
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
- The role of complete response in multiple myeloma. (2009) (217)
- International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
- Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. (2009) (201)
- High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. (1998) (200)
- Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. (1997) (199)
- Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia (2012) (198)
- Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral Environment (1999) (198)
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
- A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. (2002) (195)
- Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. (1999) (194)
- Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. (1999) (194)
- Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. (1999) (191)
- High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis (2001) (187)
- Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. (2003) (186)
- Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. (2006) (184)
- The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma (1998) (180)
- Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study (2008) (180)
- Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma (2006) (174)
- Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells (1999) (172)
- Autologous hematopoietic stem-cell transplantation for multiple myeloma. (2009) (171)
- CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. (2003) (169)
- Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. (1993) (168)
- Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations (2010) (164)
- Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. (2009) (163)
- VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. (2004) (162)
- Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study. (2008) (161)
- Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. (2009) (160)
- Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. (2008) (159)
- Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. (2005) (158)
- Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). (2010) (157)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (154)
- Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. (2003) (151)
- A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients (1998) (151)
- Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (2008) (150)
- Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. (1995) (149)
- Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. (2010) (149)
- Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B (2000) (147)
- Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. (1996) (146)
- Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. (2014) (144)
- Survival and years of life lost in different age cohorts of patients with multiple myeloma. (2010) (142)
- Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. (2003) (141)
- A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. (2007) (140)
- Mcl-1 Regulation and Its Role in Multiple Myeloma (2004) (138)
- Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma (2010) (137)
- CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia (2002) (136)
- A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. (2007) (135)
- A pivotal role for Mcl-1 in Bortezomib-induced apoptosis (2008) (128)
- Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. (2011) (126)
- Current status of autologous stem cell transplantation for multiple myeloma (2019) (125)
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. (2009) (125)
- The cancer germ‐line genes MAGE‐1, MAGE‐3 and PRAME are commonly expressed by human myeloma cells (2000) (124)
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? (2011) (124)
- Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). (2005) (122)
- Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. (2005) (121)
- A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia (1998) (119)
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma (2010) (116)
- Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. (2011) (116)
- Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) (2015) (115)
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (2011) (114)
- Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma (2007) (114)
- Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the french registry on autologous transplantation in multiple myeloma (1995) (114)
- Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma (2005) (113)
- Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. (1996) (113)
- The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (2008) (111)
- CD28, a marker associated with tumoral expansion in multiple myeloma. (1998) (110)
- Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study (2011) (110)
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. (2010) (109)
- Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma (2008) (108)
- Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. (2008) (107)
- Monoclonal gammopathy of undetermined significance: a consensus statement (2010) (107)
- Long-term complications of total body irradiation in adults. (2001) (107)
- A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). (1998) (105)
- Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. (2002) (105)
- Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. (1995) (101)
- High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization (1999) (100)
- Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. (1995) (100)
- Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. (2008) (99)
- Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02. (2010) (98)
- Therapy-related acute promyelocytic leukemia: a report on 16 cases. (1992) (98)
- t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma (2003) (97)
- A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study (2011) (97)
- High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. (2010) (96)
- Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. (2013) (96)
- Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective (2010) (94)
- Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. (1999) (94)
- Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. (2006) (94)
- Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group (2010) (94)
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma (2008) (93)
- Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). (1996) (92)
- High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. (2000) (91)
- Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. (2000) (90)
- Multiple myeloma. (1997) (89)
- Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte. (1999) (88)
- Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells (2002) (87)
- Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie. (1998) (86)
- Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials (2007) (86)
- Individualizing treatment of patients with myeloma in the era of novel agents. (2008) (85)
- Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). (2002) (85)
- Viridans streptococcal bacteraemia in patients with neutropenia (1995) (85)
- Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. (2003) (85)
- Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial (2008) (85)
- A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. (2007) (84)
- VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial. (2007) (84)
- Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. (2008) (83)
- Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. (2013) (81)
- Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. (1999) (81)
- Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients (2012) (81)
- A combination of anti‐interleukin 6 murine monoclonal antibody with dexamethasone and high‐dose melphalan induces high complete response rates in advanced multiple myeloma (2000) (79)
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group (2010) (79)
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
- The role of autologous hematopoietic stem cell transplantation in multiple myeloma. (1997) (77)
- Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. (2004) (76)
- High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. (1986) (75)
- P53 deletion is not a frequent event in multiple myeloma (1999) (75)
- Monoclonal antibodies in the treatment of multiple myeloma (2011) (75)
- Hematopoietic stem cell transplantation in multiple myeloma. (2009) (75)
- Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. (2010) (74)
- Relapsed refractory multiple myeloma: a comprehensive overview (2019) (74)
- VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial. (2006) (74)
- Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2010) (73)
- Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. (2011) (72)
- CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. (2005) (72)
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy (2008) (70)
- Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours (2005) (70)
- The Clinical Spectrum of IgM-Related Amyloidosis: A French Nationwide Retrospective Study of 72 Patients (2008) (69)
- Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. (2008) (69)
- Genetic variation associated with bortezomib-induced peripheral neuropathy (2011) (68)
- Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. (2006) (67)
- Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. (1995) (67)
- Lenalidomide maintenance after transplantation for myeloma. (2010) (66)
- Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (2011) (66)
- Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia (1998) (66)
- Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. (2016) (65)
- Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia (2007) (65)
- False-positive hepatitis C virus antibody tests in paraproteinaemia (1990) (64)
- Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. (1989) (64)
- Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. (2011) (64)
- Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma. (2005) (61)
- Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. (2012) (61)
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial. (2005) (61)
- Epstein–Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation (1999) (59)
- FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease (2006) (59)
- Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. (2008) (57)
- CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. (2008) (57)
- Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy (1999) (56)
- Amplification of the 11q23 region in acute myeloid leukemia (1999) (56)
- Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers (2014) (55)
- Lack of CD27 in myeloma delineates different presentation and outcome (2006) (55)
- Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin (2010) (54)
- Efficacy and outcome of autologous transplantation in rare myelomas (2009) (54)
- Thalidomide in patients with advanced multiple myeloma. (2000) (53)
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients (2012) (53)
- Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. (2003) (52)
- Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study (2018) (51)
- Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02). (2004) (50)
- Randomized trial experience of the Intergroupe Francophone du Myélome. (2001) (50)
- Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl‐1 anti‐apoptotic molecule (2001) (50)
- Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection (1993) (50)
- High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. (1996) (50)
- Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. (1996) (50)
- Clonal Hematologic Disorders in Down Syndrome A Review (1995) (50)
- How I treat first relapse of myeloma. (2017) (50)
- Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. (2002) (49)
- Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas (1997) (48)
- Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial (1990) (48)
- TREATMENT OF ESSENTIAL THROMBOCYTHAEMIA BY ALPHA 2a INTERFERON (1988) (48)
- Haemophagocytic syndrome associated with infections. (2000) (47)
- Pharmacokinetics of Itraconazole Oral Solution in Neutropenic Children during Long-Term Prophylaxis (2001) (46)
- Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma. (2004) (45)
- Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. (1996) (45)
- Standard therapy versus autologous transplantation in multiple myeloma. (1997) (45)
- Rituximab in CD20 positive multiple myeloma (2007) (44)
- The role of stem cell transplantation in multiple myeloma. (2002) (44)
- Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. (2012) (43)
- High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells (1995) (43)
- Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. (2012) (43)
- Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary Results of an IFM Phase II Study (2005) (42)
- Autologous stem cell transplantation (2004) (42)
- Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group (2014) (41)
- A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma (2008) (41)
- Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. (2009) (41)
- Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. (1997) (41)
- Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry (2014) (41)
- High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial. (2009) (39)
- Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. (2011) (39)
- Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. (2004) (38)
- A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01-02 study. (2006) (38)
- Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) (2006) (37)
- Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. (2005) (37)
- Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. (2004) (37)
- Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. (2009) (37)
- Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study. (2004) (37)
- Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues (2007) (37)
- Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography (2008) (36)
- The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. (2007) (36)
- Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma (2004) (36)
- Intensive short term therapy with granulocyte‐macrophage–colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia (1999) (36)
- Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM) (2009) (35)
- Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. (2005) (35)
- An interleukin 1 receptor antagonist blocks the IL-1-induced IL-6 paracrine production through a prostaglandin E2-related mechanism in multiple myeloma. (1995) (35)
- Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. (2011) (34)
- Maintenance therapy in multiple myeloma (2009) (34)
- Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. (2014) (34)
- Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study. (2017) (34)
- Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. (2010) (33)
- Stem cell transplantation in multiple myeloma (0, 1, or 2) (2005) (33)
- The retinoblastoma susceptibility gene RB-1 in multiple myeloma. (1997) (33)
- A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity (1996) (33)
- High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. (2005) (32)
- Inhibiting IL-6 in human multiple myeloma. (1992) (32)
- The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials. (2006) (32)
- Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study. (2010) (32)
- Acute myeloid leukemia in the elderly. (1998) (31)
- Ovarian transposition by laparoscopy before radiotherapy in the treatment of hodgkin's disease (1998) (30)
- Ten years of improvement in the management of multiple myeloma: 2000-2010. (2010) (30)
- Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. (1987) (30)
- International uniform response criteria for multiple myeloma (2007) (30)
- Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin (2010) (30)
- Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma (2009) (29)
- Role of stem cell transplantation. (2007) (29)
- Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution (2016) (29)
- Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial (2007) (29)
- Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study (2010) (28)
- Induction therapy in multiple myeloma. (2008) (28)
- Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. (2017) (27)
- Plasma cell growth fraction using Ki‐67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I (2007) (27)
- Comprehensive Review of AL amyloidosis: some practical recommendations (2021) (27)
- Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design (2004) (27)
- Thalidomide in multiple myeloma: past, present and future. (2006) (27)
- Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients. (2004) (27)
- Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center. (2006) (26)
- Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage. (1999) (26)
- JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5 (2010) (26)
- The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study. (2006) (26)
- Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation (2010) (26)
- Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma. (2007) (26)
- LEADING ARTICLE International uniform response criteria for multiple myeloma (2006) (25)
- Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. (1999) (25)
- CYTOKINE THERAPY IN MULTIPLE MYELOMA* (1996) (25)
- Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). (1997) (25)
- Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma (2016) (24)
- Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases (2009) (24)
- Role of autologous stem-cell transplantation in multiple myeloma. (2007) (24)
- Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (24)
- Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. (2011) (23)
- Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study. (2004) (23)
- Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3‐ITD molecular status for cytogenetically normal AML patients: A GOELAMS study (2012) (22)
- Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. (2004) (22)
- [Hemophagocytic syndromes. A series of 23 cases]. (1996) (22)
- Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate‐dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy (1990) (21)
- Comparative genomic hybridization is a powerful tool, complementary to cytogenetics, to identify chromosomal abnormalities in childhood acute lymphoblastic leukaemia (1997) (21)
- Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy. (2008) (21)
- Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells. (1999) (21)
- Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation (2012) (20)
- Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02 (2010) (20)
- Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome (2012) (20)
- Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2005) (20)
- Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone (2008) (20)
- A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients (1999) (20)
- Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial. (2009) (20)
- Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients. (1991) (19)
- A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results. (1993) (19)
- Persistence of CD33 expression at relapse in CD33+ acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease (2008) (19)
- Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. (1987) (19)
- Farnesyltransferase inihibitors in hematologic malignancies. (2007) (19)
- Essential role for the p 110 δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia (2005) (19)
- Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression (2011) (18)
- Reactive plasmacytoses can mimick plasma cell leukemia: Therapeutical implications (2007) (18)
- Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma (2005) (18)
- Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. (2011) (18)
- Hematologic Profiles in the Phase 3 APEX Trial. (2005) (18)
- Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. (1998) (18)
- Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results. (2009) (18)
- CD130 rather than CD126 expression is associated with disease activity in multiple myeloma (1999) (18)
- Management of multiple myeloma. (2002) (18)
- [Rare pulmonary mycoses in patients with hematologic diseases]. (1998) (17)
- Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312) (2004) (17)
- Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study (2010) (17)
- Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide/Dexamethasone Who Achieve a Complete or near Complete Response Have Longer Overall Survival and Time to Progression Compared with Patients Achieving a Partial Response. (2007) (17)
- A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. (2009) (17)
- Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy. (2017) (17)
- Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia (2008) (17)
- Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor (2012) (17)
- Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study (2010) (17)
- Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. (2013) (17)
- Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies (2012) (16)
- Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression (2008) (16)
- Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases. (2006) (16)
- A 5′ splice region G → C mutation in exon 3 of the human β‐spectrin gene leads to decreased levels of β‐spectrin mRNA and is responsible for dominant hereditary spherocytosis (spectrin Guemene‐Penfao) (1998) (16)
- Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02). (2009) (16)
- Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. (2019) (16)
- Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone (2007) (16)
- The role of high-dose therapy with autologous stem cell support in the era of novel agents. (2009) (16)
- Immunoglobulins D and M multiple myeloma variants are heavily mutated. (1997) (15)
- Rothmund-Thomson syndrome and osteosarcoma. (1996) (15)
- Treatment of acute myeloblastic leukemia in adults. The GOELAM experience. (1996) (15)
- Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study. (2009) (15)
- Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. (2017) (15)
- Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma (2008) (15)
- Stem-cell transplantation in multiple myeloma. (2005) (15)
- Autologous peripheral blood progenitor cell transplantation for multiple myeloma. (1999) (15)
- Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide (2008) (15)
- High dose radiochemotherapy followed by autologous stem cell transplantation in four patients with multiple lymphomatous polyposis (1995) (14)
- Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products. (1997) (14)
- A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma (2010) (14)
- COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE (2016) (14)
- Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients? (2012) (14)
- Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: Results at high cumulative doses of 90Y (2008) (14)
- Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia (2002) (13)
- The allogeneic dilemma (2007) (13)
- 13q14 deletions are not primary events in B-cell chronic lymphocytic leukemia: a study of 100 patients using fluorescence in situ hybridization. (1996) (13)
- Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study. (2010) (13)
- Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors (2010) (13)
- Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. (2013) (12)
- Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma. (2009) (12)
- When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). (2009) (12)
- Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors (2009) (12)
- Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT (2009) (12)
- Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma (2010) (12)
- NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation. (2005) (11)
- Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. (1990) (11)
- Evolving role of stem cell transplantation in multiple myeloma. (2005) (11)
- Shaping European Early Dialogues: The Seed Project. (2015) (11)
- The use of GM-CSF and G-CSF in the treatment of acute leukemias. (1995) (11)
- TREATMENT OF ACUTE NON-LYMPHOBLASTIC LEUKAEMIA IN ELDERLY PATIENTS (1984) (11)
- Multiple myeloma. (2001) (10)
- A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials. (2005) (10)
- A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population (2010) (10)
- Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin’s Lymphoma (2012) (10)
- Bortezomib (BOR) and High Dose Melphalan (HDM) as Conditioning Regimen Before Autologous Stem Cell Transplantation (ASCT) for De Novo Multiple Myeloma (MM): Final Results of the IFM Phase II Study VEL/MEL (2008) (10)
- Identification of Molecular Predictors of Response to ZARNESTRA™ (Tipifarnib, R115777) in Relapsed and Refractory Acute Myeloid Leukemia. (2004) (10)
- Collagen gel cultures for detection of spared hematopoietic progenitors in Asta Z 7557 purged human marrows. (1990) (9)
- Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy. (2000) (9)
- Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome. (2007) (9)
- Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. (1999) (9)
- Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs (2009) (9)
- The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group. (1996) (9)
- Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study. (2009) (9)
- Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study. (2016) (9)
- [Treatment of localized forms of Hodgkin's disease with 3 courses of chemotherapy (ABVD-MP) in combination with wide focal and prophylactic lumbo-splenic radiotherapy. The POF 81/12 protocol]. (1989) (9)
- Cerebrospinal fluid neopterin levels in children with central nervous system leukemia. (1993) (8)
- Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation (2010) (8)
- Maintenance treatment in multiple myeloma. (2008) (8)
- The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure. (2007) (8)
- Reactive plasmacytoses in multiple myeloma during hematopoietic recovery with G- or GM-CSF. (2000) (8)
- Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial. (2009) (8)
- New treatments in multiple myeloma: beyond optimal treatment. (2008) (8)
- Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications. (2006) (8)
- Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens (2008) (8)
- Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study. (2006) (8)
- Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has). (2014) (8)
- Multiple myeloma. (2004) (8)
- Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update (2022) (8)
- Bortezomib Plus Dexamethasone Versus Reduced-dose Bortezomib Plus Thalidomide-dexamethasone As Induction Prior To Autologous Transplantation in Newly Diagnosed Myeloma (2010) (7)
- Long-term results of total abdominopelvic irradiation in non-Hodgkin's lymphomas after failure of chemotherapy. (1998) (7)
- Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study. (2002) (7)
- The evolving background for high-dose treatment for myeloma (2007) (7)
- High-dose therapy in multiple myeloma. (2002) (7)
- Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab (2004) (7)
- [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. (2000) (7)
- Handbook of Multiple Myeloma (2015) (7)
- Intermediate-risk childhood acute lymphoblastic leukemias: amsacrine + cytosine arabinoside versus intermediate-dose methotrexate for consolidation, and 6-mercaptopurine + methotrexate + vincristine versus monthly pulses for maintenance. (1987) (7)
- Improved Outcome with Androgens as Maintenance Treatment in Elderly Patients with Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the GOELAMS SA-2002 Multicenter Phase III Randomized Open Trial (2008) (7)
- Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). (2010) (7)
- Stem cell transplantation in multiple myeloma. (2007) (6)
- A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results. (1991) (6)
- Autologous transplantation for multiple myeloma. (2008) (6)
- Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach (2010) (6)
- Requirements for operational cure in multiple myeloma. (2021) (6)
- How to select among available options for the treatment of multiple myeloma. (2012) (6)
- Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma. (2009) (6)
- [Allogenic bone marrow grafts in acute myeloid leukemias. A retrospective study in 111 grafted patients in first complete remission]. (1986) (6)
- Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT (2008) (5)
- Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies. (2006) (5)
- Multiple myeloma in the elderly: when to treat, when to go to transplant. (2010) (5)
- Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma. (2007) (5)
- Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (5)
- Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study. (2009) (5)
- Vinorelbine (VRL) in patients with recurrent multiple myeloma (MM): A phase II study (1997) (5)
- Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later (2009) (5)
- Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
- Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation (2015) (5)
- Blockade of p110delta isoform activity of phosphoinositide 3-kinase inhibits blast cell proliferation in acute myeloblastic leukemia. (2004) (5)
- Integrating Novel Therapies in the Transplant Paradigm (2009) (5)
- Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study. (1987) (5)
- Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: long-term follow-up in 35 cases. (1998) (5)
- [Thymus hyperplasia following chemotherapy]. (1996) (5)
- Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant. (2007) (4)
- Increasing Hemoglobin Levels with Epoetin Alfa in Anemic Hematologic Cancer Patients Receiving Chemotherapy Correlates Significantly with Improved Quality of Life. (2004) (4)
- A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. (2003) (4)
- Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma. (2009) (4)
- HLA-DPB and susceptibility to hodgkins disease (1993) (4)
- Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity. (2008) (4)
- Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment. (2009) (4)
- Intensive therapy in multiple myeloma. (1999) (4)
- Optimising patient outcomes in myeloma. (2010) (4)
- Gentuzumab-Ozogamicin (GO) Plus Idarubicin (I) and Cytarabine (C) as Induction Treatment for Elderly Patients with Poor-Risk Cytogenetics Acute Myeloid Leukemia (AML). (2007) (4)
- Probable disseminated cerebral aspergillosis: recovery with medical treatment. (1994) (4)
- Application of the study of prognostic factors to the treatment of childhood (less than 20 years old) acute lymphoblastic leukemia. (1980) (4)
- [Thrombotic manifestations and acute distal ischemia in primary antiphospholipid syndrome in children]. (1992) (4)
- Allografting or autografting for myeloma. (2007) (4)
- Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients (2010) (4)
- Localized lnvasive Pulmonary Aspergillosis in Patients with Neutropenia (1993) (4)
- [Bronchopulmonary manifestations of Horton's disease. Apropos of a case]. (1983) (3)
- Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Lymphocytic Leukemia: a Long Term Analysis From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). (2009) (3)
- Light Chain Escape in Multiple Myeloma (2018) (3)
- Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma. (2007) (3)
- myeloma autologous stem cell transplantation in newly diagnosed multiple thalidomide plus dexamethasone as induction treatment before Bortezomib plus dexamethasone versus reduced-dose bortezomib, (2012) (3)
- [Multiple myeloma]. (1995) (3)
- A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination with Melphalan and Dexamethasone in Subjects with Newly-Diagnosed Light-Chain (AL)-Amyloidosis. (2008) (3)
- Priming with GM-CSF for acute myelogenous leukemia (AML): GOELAM data. (2004) (3)
- Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Treatment for Elderly Patients with Acute Myeloid Leukemia (1997) (3)
- Prognostic Value of the ‘Monosomal Karyotype’ Entity in Elderly Patients with AML: a GOELAMS Study of 186 Patients with Unfavourable Cytogenetic Abnormalities. (2009) (3)
- High-dose therapy in multiple myeloma. (2002) (3)
- [Leukemias induced by anticancer chemotherapies]. (1999) (3)
- The Role of Colony-Stimulating Factors in the Treatment of Acute Leukaemia (1997) (3)
- Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM) (2007) (3)
- Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: Total Body Irradiation (TBI) Plus Cyclophosphamide (or Melphalan) Is Not Superior to BEAM, A Single Institution Experience (2010) (3)
- [Acquired Willebrand syndrome with lymphoproliferative disorders]. (1997) (3)
- Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials. (2009) (3)
- Bortezomib in multiple myeloma: treatment approach and outcomes (2004) (3)
- Role of bone marrow transplantation in the disease pathway of myeloma. (2007) (3)
- Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has). (2014) (3)
- Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma (2004) (2)
- Allogeneic, autologous bone marrow transplantation and chemotherapy in first remission of adult acute lymphoblastic leukemia. Prospective study LALA87. Long term results (1999) (2)
- Evolution of Antithrombin (AT) and Fibrinogen (Fg) Levels during Induction Chemotherapy with L-Asparaginase (Asp) in Adult Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). Clinical Outcomes and Use of Coagulation Supportive Treatments: The CAPELAL Study. (2004) (2)
- The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency (2008) (2)
- Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. (2004) (2)
- Surgical treatment of a foscavir-resistant atypical Cytomegalovirus pneumonia in an allogeneic stem cell transplant recipient (2008) (2)
- [Treatment of febrile episodes in neutropenic children by ceftazidime combined with netilmicin. Results of a multicenter study apropos of 88 cases]. (1987) (2)
- Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study (1992) (2)
- [Comparison between bone marrow autograft and intensive chemotherapy as treatment for maintenance of complete remission in acute myeloblastic leukemia in the adult. GOELAM Group]. (1993) (2)
- Cutaneomucous side effects of hydroxyurea: prospective study on 27 patients. (2006) (2)
- Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT), (2011) (2)
- Autologous Hematopoietic Cell Transplantation in Multiple Myeloma (2014) (2)
- Rituximab in CD20 Positive Multiple Myeloma: A Prospective Study from the IFM Group. (2006) (2)
- Interest of Non-Myeloablative Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma: A Multicenter Retrospective Study. (2008) (2)
- High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkin’s Lymphoma: An Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years (2008) (2)
- Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma–a “France autogreffe” study (1994) (2)
- Multiple myeloma. (2018) (2)
- [Course of refractory anemias. Study of 49 cases]. (1974) (2)
- A Multicenter Randomized Comparison of Maintenance Treatment with Androgens in Elderly Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the Goelams-2002 Study. (2006) (2)
- Two new hemoglobin variants with increased oxygen affinity: Hb Nantes [beta34(B16)Val-->Leu] and Hb Vexin [beta116(G18)His-->Leu]. (2003) (2)
- A235 A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP (2009) (2)
- myeloma cells apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated (2011) (1)
- MIDAM Regimen (Mylotarg + Intermediaite Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients. (2006) (1)
- The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma (2008) (1)
- [Role of glucocorticoids in the treatment of multiple myeloma]. (1996) (1)
- Treatment of Philadelphia Chromosome Positive ALL with Interferon Alpha (1996) (1)
- Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia Comparison of Autologous Bone Marrow Transplantation and Intensive (1997) (1)
- Clinical management of myeloma--state of the art. (2010) (1)
- [Osteomedullary amyloidosis with osteolytic lesions. Apropos of 4 cases]. (1986) (1)
- Respective PROGNOSTIC Value of the International Harmonization PROJECT (IHP), Gallamini and London Criteria for Interim FDG PET-CT Performed AFTER 4 Courses of ABVD IN HODGKIN'S LYMPHOMA (2010) (1)
- High-dose chemotherapy followed by autologous stem-cell transplantation in liver-transplanted multiple myeloma patients: a report of two cases. (2009) (1)
- Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire. (2008) (1)
- Toxicity Profile of Idarubicin: Experiences with Oral and Intravenous Idarubicin in the Treatment of Leukemia (1992) (1)
- CAR-T cell therapy in myeloma: hopes and hurdles (2023) (1)
- TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells (2010) (1)
- [Cerebral granulocytic sarcoma disclosing acute non-lymphoblastic leukemia]. (1991) (1)
- Human chimeric anti-CD44 antibody ARH460-16-2 binds leukemic cells and malignant plasma cells (2008) (1)
- [Improved results in the treatment of acute monoblastic leukemia: analysis of 91 patients treated in the 01 AM 81 protocol]. (1987) (1)
- High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients with Multiple Myeloma (2010) (1)
- [Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3]. (2001) (1)
- AML with 11q23/MLL Abnormalities: A Survey of 146 Cases from French AML Intergroup. (2006) (1)
- [Intensive treatment of multiple myeloma]. (2003) (1)
- Daratumumab in transplant regimens for myeloma? (2020) (1)
- [Hepatic granulomatous localizations in Whipple's disease. Apropos of 2 cases]. (1984) (1)
- Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and toxicity (2007) (1)
- [Neonatal acute leukemia: apropos of 7 cases]. (1995) (1)
- Two cases of acute lymphoblastic leukaemia following acute myeloid leukaemia. (2008) (1)
- Safety and Efficacy of Caspofungin as Preventive and Empirical Antifungal Treatment of Neutropenic Allografted Patients. (2004) (1)
- Emergence of Mucormycosis in Onco-Hematology after Prolonged Use of Voriconazole: Attention Required. (2004) (1)
- [Autograft of hematopoietic stem cells in multiple myeloma]. (2003) (1)
- New insights into the biology and advances in the management of multiple myeloma. (2007) (1)
- The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma (2008) (1)
- Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas (2008) (1)
- 110 cases from the French AML Intergroup Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of (2013) (1)
- Hierarchical Evaluation of Baseline Poor-Prognosis Factors and Response to Initial Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL) Treated in the Risk-Adapted GRAALL-2003 Study. (2005) (1)
- Comparing the Performance of Serum Free Light Chain Measurements with Urine Electrophoresis and Immunofixation for Monitoring and Assessing Response to Therapy in Patients with Multiple Myeloma (2014) (1)
- High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients. (2007) (1)
- Reply to K. Filanovsky et al (2010) (1)
- Overexpression of Her-2/neu Is Observed in One Third of Adult B-ALL Patients and Is Associated with Chemoresistance in These Patients. (2004) (1)
- Hb Potomac [β101(G3)Glu→Asp] in a Polish Family Living in France (1987) (1)
- Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle (2010) (1)
- Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD). (2016) (0)
- randomized study in adult de novo acute myelogenous leukemia Quinine as a multidrug resistance inhibitor: a phase 3 multicentric (2013) (0)
- Hematopoietic cell transplantation in multiple myeloma (2004) (0)
- Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia. (1990) (0)
- Acute Lymphoblastic Leukemia Occurring in Patient with Acute Myeloid Leukaemia: An Unrelated Leukemia Rather Than a Therapy-Related Malignancy. About 2 Cases. (2006) (0)
- [Role of chemotherapy in the treatment of esthesioneuroblastoma in children. Apropos of 3 case reports]. (1988) (0)
- Contents Vol. 70, 2006 (2007) (0)
- Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group (2008) (0)
- Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH). (2023) (0)
- Subject Index Vol. 70, 2006 (2007) (0)
- multiple myeloma autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo followed by a dose-reduced allograft (IFM99-03 trial) with tandem Prospective comparison of autologous stem cell transplantation (2013) (0)
- Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1. (2007) (0)
- Abstract session I–Transplantation (2004) (0)
- Durable responses with 90Y-epratuzumab fractionated radioimmunotherapy (RAIT) in NHL (2009) (0)
- Abstract8.6-02 Genomic HLA class II typing (DR, DQ and DP specificities), primary mixed lymphocytes reaction and G.V.H. disease: Retrospective study of 41 allogeneic marrow transplantations (1989) (0)
- High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls. (2008) (0)
- Mylotarg 9 mg/m² Combined with Intermediate Dose Aracytin and Mitoxantrone (MIDAM) in Relapsed/Refractory CD33+ Acute Myeloid Leukemia: A Single Center Phase II Experience. (2004) (0)
- How Treat How I treat fi rst relapse of myeloma (2017) (0)
- [Use of interferon alpha in multiple myeloma]. (1996) (0)
- Development of genomic markers that predict response to molecularly targeted antileukemic therapy. (2008) (0)
- Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial (1999) (0)
- Allogeneic Stem Cell Transplantation (Allo-SCT) for Relapsed/Refractory T Cell Lymphomas in Adults: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). (2006) (0)
- Traitement intensif du myélome multiple. Discussion (2003) (0)
- [Systemic mastocytosis and malignant hemopathies. Review of the literature apropos of a case]. (1991) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs. (2012) (0)
- Is the MELR a good test to predict the occurrence of acute GvHD in bone marrow transplantation between genotypic HLA-identical pairs? (1991) (0)
- Selection of fully human anti-CD138 for detecting and therapy of multiple myeloma from combinatorial libraries and generation of novel anti-myeloma antibodies (2005) (0)
- [Myeloma. Physiopathology, diagnosis, principles of treatment]. (1992) (0)
- Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française de Greffe de Moelle Thérapie Cellulaire (SFGM-TC). (2009) (0)
- [Acute myeloblastic leukemias. Diagnosis, clinical course and prognosis]. (1989) (0)
- The treatment of chronic myelogenous leukemia in chronic phase with interferon alpha and cytosine-arabinoside Results of the French trials (1997) (0)
- [Association of polyglobulia and fibroma. Study of a case]. (1974) (0)
- Systematic literature review of health economic models developed for multiple myeloma to support future analyses. (2022) (0)
- Treatment of Multiple Myeloma and Related Disorders: AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA (2008) (0)
- elderly multiple myeloma patients ineligible for high-dose therapy Dexamethasone-based regimens versus melphalan-prednisone for (2011) (0)
- Mcl-1 Is Overexpressed in Multiple Myeloma and Correlates with Disease Severity. (2004) (0)
- Outcome after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality (2008) (0)
- Interleukin-l0 Is a Proliferation Factor But Not a Differentiation Factor for Human Myeloma Cells (2002) (0)
- [Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome]. (2001) (0)
- Impact Of Cyclosporine A (CsA) Concentration On The Incidence Of Severe Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) (2009) (0)
- Comparison of Intensive Chemotherapy and Autologous Transplantation as Post Remission Therapy in Adult Acute Myeloid Leukemia. Update of the GOELAM 1 Trial (2001) (0)
- Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France. (2014) (0)
- Thalidomide as maintenance therapy after autologous stem-cell transplantation (2009) (0)
- Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone. (2009) (0)
- 768 Hodgkin's disease (HD), clinical stages (CS) IA-IIIB without bulky tumor: Interim results of the goelams randomized H90-NM protocol (1995) (0)
- Impact of Cyclosporine a (CsA) Concentration on the Incidence of Severe Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT). (2008) (0)
- [Hodgkin's disease. Etiology--physiopathology]. (1984) (0)
- Posaconazole as Prophylaxis in Immunocompromised Patients: A Single Center Experience (2008) (0)
- myeloid leukemia in patients 70 years or older care, including hydroxyurea, in the treatment of newly diagnosed acute A randomized phase 3 study of tipifarnib compared with best supportive (2011) (0)
- [Autologous transplantation of hematopoietic stem cells and growth factors]. (1993) (0)
- against apoptosis VEGF induces MCL-1 upregulation and protects multiple myeloma cells (2013) (0)
- Features of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors: Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem Cell Source. (2008) (0)
- Metalloproteinase-2 Activation Its Potential Involvement in ( Matrilysin ) by Human Myeloma Cells and Production of Metalloproteinase-7 (1999) (0)
- Treatment of transplant-eligible patients (2015) (0)
- Robert Kyle lecture: Access to Innovation and Quality of Care in the Context of Economic Constraints: a Challenge for Healthcare (2015) (0)
- GVHD Prophylaxis with Cyclosporine + Mycophenolate Mofetil Improves Outcome Compared to Cyclosporine Alone in Patients Receiving Reduced Intensity Conditioning Hematopoietic Stem-Cell Transplantation from Unrelated Donor for Hematological Diseases. (2007) (0)
- Analysis of Skin Reactivity with Monoclonal Antibodies After Allogeneic Bone Marrow Transplantation (1985) (0)
- New Strategy for Allogeneic Peripheral Blood Stem Cell Transplantation After Reduced Intensity Conditioning in Multiple Myeloma: Interim Analysis of the IFM2005-03 Study. (2009) (0)
- [Methods for evaluating biological response modifiers]. (1998) (0)
- Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Unrelated Umbilical Cord Blood Transplantation (UCBT) (2010) (0)
- A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France. (2014) (0)
- Factors Predicting Allogeneic Peripheral Blood Stem Cell (PBSC) Mobilization After G-CSF Treatment in Healthy Donors (2009) (0)
- Recent Advances of Thalidomide in the Treatment of Multiple Myeloma (2008) (0)
- Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2. (2009) (0)
- [Evaluation of interferons in hemato-oncology]. (1989) (0)
- Prognosis Value of [ 18 f] FDG-PET Prior Versus after Autologous Stem Cells Transplantation in High Grade Non-Hodgkin’s Lymphoma. (2008) (0)
- [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin]. (1996) (0)
- Fluorescence I n S itu H ybridization o n P eripheral-Blood Specimens I s a R eliable M ethod t o E valuate C ytogenetic Response i n C hronic M yeloid L eukemia (2000) (0)
- Donor Lymphocyte Infusions (DLI) for the Treatment of Disease Relapse in Hematological Malignancies Following Allogeneic Transplantation: Similar Efficacy Following RIC or Myeloablative Regimen (2008) (0)
- A051 Long-Term Follow-up Results of IFM9903 and IFM9904 Trials: RIC Versus ASCT (2009) (0)
- Deletions Are Not Primary Events in B-Cell Chronic Lymphocytic Leukemia : A Study of 100 Patients Using Fluorescence in Situ Hybridization 1 (2005) (0)
- Comparison of the clinical sensitivity of two free light chain assays in a cohort of light chain multiple myeloma patients (2015) (0)
- Up-front ixazomib in older patients with myeloma. (2021) (0)
- Gene Expression Profiling Comparison between the Major Mature B-Cell Neoplasms and Their Normal Cellular and Anatomic Counterparts: Identification of Candidate Genes Potentially Involved in Lymphomagenesis. (2006) (0)
- [Granulomatous hepatic localizations in Whipple's disease. Apropos of 2 cases]. (1983) (0)
- Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies. (2009) (0)
- Patient and Caregiver Experience Decision Factors in Treatment Decision Making-Results of a Systematic Literature Review of Multiple Myeloma Decision Aids. (2022) (0)
- Long-term complications of total body irradiation from a cohort of 186 patients (1998) (0)
- [A cure for multiple myeloma?]. (2006) (0)
- Sequencing anti-BCMA therapies in myeloma. (2023) (0)
- [New therapeutic approaches in multiple myeloma]. (1989) (0)
- Interest of positron emission tomography using 18FDG (FDG-PET) to guide biopsy in the detection of Richter's transformation (RT) of indolent lymphoma (2007) (0)
- Reply to J.C. Regelink et al (2010) (0)
- 5-Azacytidine (5-AZA) Salvage Therapy for Very High Risk Acute Myeloid Leukemia (AML): Response After 3 Cycles Is the Major Determinant for Outcome. (2009) (0)
- Gamma groceries. (1998) (0)
- VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis. (2004) (0)
- [Intensive induction and early consolidation of acute lymphoid leukemia in the adult. A pilot study of feasibility and long-term development]. (1989) (0)
- In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5 (2008) (0)
- Is GvHD after allogeneic bone marrow transplantation linked to any HLA DR or DP antigens (1992) (0)
- ElotuzumabinCombinationWithLenalidomideandLow-Dose DexamethasoneinRelapsedorRefractoryMultipleMyeloma (2012) (0)
- Management of multiple myeloma first relapse after autologous hematopoietic stem cell transplantation (2016) (0)
- Syndrome d'activation des macrophages: étude rétrospective de 21 observations (1992) (0)
- Antithymocyte Globulins (ATG) as Part of the Myeloablative Conditioning (MAC) Regimen Can Reduce the Risk of Severe Graft-Vs.-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT) from Matched-Unrelated Donors (MUD). (2008) (0)
- [Intracardiac metastases of primary neuroectodermal tumor]. (1992) (0)
- Interferon Alpha and Cytosine Arabinoside in the Treatment of Chronic Myelogenous Leukemia (1998) (0)
- Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma. (2004) (0)
- FDG PET for staging and therapeutic evaluation in patients with plasmocytoma (2007) (0)
- Oral Idarubicin and Low Dose Cytarabine as the Initial Treatment of Acute Myeloid Elderly Patients in Leukemia (1991) (0)
- Allogeneicstem cell transplantation for patients with Waldenstrms Macroglobulinaemia. Analysis of 106 cases from the European bone marrow registry (EBMT) (2007) (0)
- Myeloma Cell Self-Renewal Depends on JAG2 Expression and Is Mediated by IGF1 or SCF Loop (2010) (0)
- inhibitor tipifarnib in acute myeloid leukemia A 2-gene classifier for predicting response to the farnesyltransferase (2007) (0)
- report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma (2011) (0)
- Prognostic Value of Cytogenetics in Patients with Acute Myeloid Leukemia Aged More Than 60 Years at Diagnosis: Identification of Subgroups Taking Benefit from Intensive Chemotherapy. Results from a Large Single Center Retrospective Study. (2007) (0)
- Allogeneic Stem Cell Transplantation with Reduced Intensity Conditionning Regimen (RIC) for Adult Patients with AML: Same Results in Secondary and De Novo AML. (2006) (0)
- Influence of NPM1 and FLT3-ITD Status On Outcome in Relapsed/Refractory AML Patients with Normal Karyotype and Receiving Salvage Therapy Including Gemtuzumab Ozogamicin (GO). (2009) (0)
- Plasma Cell Proliferation Using Ki67 Antigen Expression Defines Subgroups Related to Short Survival in Multiple Myeloma Especially with Low Beta-2 Microglobulin. (2006) (0)
- Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). (2007) (0)
- Fludarabine, Low Dose Busulfan and Antithymocyte Globulin for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT). (2009) (0)
- Prior Treatment with Chemotherapy Associated to Gemtuzumab Ozogamicin (GO) Does Not Increase the Risk of Veno-Occlusive Disease (VOD) after Allogeneic Stem Cell Transplantation (all-SCT). (2008) (0)
- (IFM) myeloma: a phase 2 study of the Intergroupe Francophone du Myélome autologous stem cell transplantation in patients with de novo multiple Bortezomib and high-dose melphalan as conditioning regimen before (2013) (0)
- Clonal Chromosomal Abnormalities in Philadelphia Negative Cells during Dasatinib Treatment in Five Patients with Chronic Myeloid Leukemia. (2006) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation Cures CLL: A Retrospective Analysis from the SFGM-TC Registry. (2006) (0)
- What is the impact of accreditation recommendations on healthcare organisations ? A pilot study of accreditation data Summary Division for the improvement of quality and safety of care (2013) (0)
- O107 - HLA class II, (CA)n microsatellites markers and susceptibility to HODGKIN'S disease (1996) (0)
- Prognosis of Patients with AML Carrying 11Q23/MLL Reciprocal Translocations : A Retrospective Study of 191 Cases from the French AML-Intergroup (2008) (0)
- Efficacy of Imatinib-Based Therapy in a Patient with Resistant NUP214-ABL1 T-Cell Acute Lymphoblastic Leukemia. (2007) (0)
- Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM). (2009) (0)
- bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem (2009) (0)
- Management of Acute Myeloid Leukemia (AML) in First Relapse: Retrospective Analysis about 101 Adults Cases Receiving Homogeneous First-Line Therapy. Impact of Prognostic Factors and Treatment. (2004) (0)
- Autologous stem cell transplantation in multiple myeloma: none, one, or two? (2003) (0)
- Diffuse Large Cell Lymphoma with Sclerosis Localized to the Mediastinum (1985) (0)
- Running head: TIPIFARNIB IN REFRACTORY OR RELAPSED AML (2007) (0)
- Analysis of FDG PET Diffuse Bone Marrow Uptake in Staging of Hodgkin’s Disease: A Reflect of Disease Infiltration or Just Inflammation?. (2008) (0)
- J. Mehta, S. Singhal (eds). Myeloma (2003) (0)
- Current status of autologous stem cell transplantation for multiple myeloma (2019) (0)
- Mitoxantrone/Cytarabine with or without Quinine as a Potential MDR- Reversing Agent for the Treatment of Acute Leukemias (1996) (0)
- High Grade Non-Hodgkin’s Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis. (2006) (0)
- Treatment of Multiple Myeloma Patients Who Have Received at Least One Prior Therapy (2007) (0)
- Is intensive treatment beneficial to elderly patients with ANLL? (1993) (0)
- International grand round. Myeloma Grand Round (2001) (0)
- receiving high-dose therapy 2-microglobulin produce a powerful myeloma staging system for patients β Chromosome 13 abnormalities identified by FISH analysis and serum (2013) (0)
- 2218 Salvage extended field irradiation in disseminated follicular non-Hodgkin's lymphoma (NHL) after failure of chemotherapy (1999) (0)
- Beyond medicines’ barriers: exploring the true cost of multiple myeloma (2022) (0)
- A Scoring System Predictive of Extensive Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Stem Cell Transplantation (allo-SCT) (2011) (0)
- New strategies in transplantation therapy. (2004) (0)
- Late Events in Patients with Relapsed or Refractory Hodgkin’s Lymphoma Treated with an Autologous Stem Cell Transplantation. (2007) (0)
- Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years. (2006) (0)
- Working Party Aplastic Anaemia (2001) (0)
- Reply to C.A. Dasanu et al (2009) (0)
- Patients Under 50 Years of Age Do Not Present Specific Prognostic Characteristics: An IFM Study in 1897 Patients Under 65 Years of Age. (2009) (0)
- High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp (2010) (0)
- Intermediate-Dose Cytarabine in the Treatment of Relapsed or Refractory Leukemias (1992) (0)
- 99 CEREBRAL FLUID NEOPTERIN LEVELS IN CHILDREN WITH MENINGEAL RELAPSE OF MALIGNANT HEMOPATHY (1991) (0)
- Prolonged Fluconazole Prophylaxis Is Not Required In Patients With Acute Leukemias Or Myelodysplastic/Myeloproliferative Disorders After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): A Pair-Matched Analysis (2013) (0)
- Serum free light chain changes offer a more accurate assessment of response to therapy than urine Bence Jones protein excretion measurements in multiple myeloma (2015) (0)
- Traitement intensif du myélome multiple (2003) (0)
- melphalan-prednisone versus melphalan-prednisone analysis of the phase 3 VISTA study of bortezomib plus therapy: diagnosed multiple myeloma patients treated with nonintensive Superior outcomes associated with complete response in newly (2012) (0)
- Hb Potomac [beta 101(G3)Glu----Asp] in a Polish family living in France. (1987) (0)
- [Clinical aspects of acute leukemia]. (1980) (0)
- PCN142 Patient and Caregiver Preferences in Treatment Decision Making in Multiple Myeloma — Results of a Targeted Literature Review (2021) (0)
- Molecular Prognosis in Multiple Myeloma: The IFM Experience. (2006) (0)
- Impact of FLT3 Internal Tandem Duplication (FLT3/ITD) on the Outcome of HLA-Identical Sibling Hematopoietic Transplantation for Adult Acute Myeloid Leukemia (AML) in First Remission: Substantial Probability of Leukemia-Free Survival Despite Increased Relapse Risk. A Retrospective Analysis of the EBM (2007) (0)
- The Intergroupe Francophone du Myélome experience with thalidomide (2009) (0)
- Fludarabine, Low Dose Busulfan and Antithymocyte Globulin (ATG) Compared to Fludarabine and Low Dose Total Body Irradiation (TBI) for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) In Patients with Lymphoid Malignancies. (2010) (0)
This paper list is powered by the following services:
